Royalty Pharma (RPRX) Expected to Announce Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is expected to issue its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $1.28 per share and revenue of $839.9730 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.11 by $0.06. The company had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $42.97 on Wednesday. Royalty Pharma has a 1-year low of $29.66 and a 1-year high of $43.07. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $24.80 billion, a PE ratio of 32.55, a price-to-earnings-growth ratio of 1.62 and a beta of 0.42. The firm’s 50 day simple moving average is $39.66 and its 200 day simple moving average is $37.85.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a dividend yield of 2.2%. Royalty Pharma’s payout ratio is currently 66.67%.

Insiders Place Their Bets

In related news, CFO Terrance P. Coyne sold 69,582 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $39.35, for a total value of $2,738,051.70. Following the sale, the chief financial officer directly owned 36,010 shares of the company’s stock, valued at $1,416,993.50. This trade represents a 65.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George W. Lloyd sold 30,654 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $38.50, for a total value of $1,180,179.00. The SEC filing for this sale provides additional information. Insiders sold a total of 1,065,675 shares of company stock valued at $41,655,396 over the last quarter. 18.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC lifted its stake in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the period. Hilltop Holdings Inc. purchased a new position in shares of Royalty Pharma during the third quarter valued at about $205,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Royalty Pharma during the third quarter valued at about $213,000. Private Advisor Group LLC bought a new position in Royalty Pharma in the third quarter worth about $252,000. Finally, Osaic Holdings Inc. lifted its holdings in Royalty Pharma by 134.8% in the second quarter. Osaic Holdings Inc. now owns 7,104 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 4,078 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on RPRX shares. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday, January 22nd. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Friday. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Finally, Morgan Stanley dropped their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Royalty Pharma has an average rating of “Moderate Buy” and an average target price of $47.50.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.